Cyclin G1 inhibitors and related methods of treating cancer
AssigneeDelta Next-Gene, LLC
InventorsErlinda M. Gordon, Frederick L. Hall
Life of this patent
Estimating the term…
Abstract
Methods of treating a cancer in a patient are provided. The methods can include obtaining a tumor sample from a patient, detecting whether CCNG1 gene expression is present in the tumor sample, diagnosing the patient with a CCNG1 inhibitor-responsive cancer when the presence of CCNG1 gene expression in the tumor sample is detected, and/or administering an effective amount of a CCNG1 inhibitor to the diagnosed patient. CCNG1 inhibitors can include a viral vector having a binding peptide that is configured to bind one or more signature (SIG) elements of an invading tumor and at least one cytocidal gene. CCNG1 inhibitors including cell penetrating peptides are also provided.
Claims18
A method of treating a cancer in a patient, the method comprising:
- obtaining a tumor sample from a patient;
- detecting whether Cyclin G1 (CCNG1) gene expression is present in the tumor sample;
- diagnosing the patient with a CCNG1 inhibitor-responsive cancer when the presence of CCNG1 gene expression in the tumor sample is detected;
- and
- administering an effective amount of a viral vector encoding the CCNG1 inhibitor to the diagnosed patient, wherein the CCNG1 inhibitor consists of a polypeptide consisting of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, or SEQ ID NO:25.
A Cyclin G1/dnG1-derived cell cycle blocking peptide (CCBP) coupled to a cell penetrating peptide (CPP), wherein the CCBP comprises a polypeptide sequence consisting of a polypeptide selected from:
- (SEQ ID NO:
- 22)
- RFTVSDLMRMEKIVLEKVTWK;
- (SEQ ID NO:
- 23)
- KACHCRIIFSKAKPSVLALSIIA;
- (SEQ ID NO:
- 24)
- RIIFSKAKPSVLALSIIALEIQA;
- or
- (SEQ ID NO:
- 25)
- RQLKHSYYRITHLPTIPEMVP.
Dependencies are inferred from the claim text.